Literature DB >> 19584974

Bivalirudin as an anticoagulant for simultaneous integrated coronary artery revascularization - a novel approach to an inherent concern.

R Scott McClure1, Jennifer Higgins, Stuart A Swinamer, Reiza Rayman, Wojciech B Dobkowski, William J Kostuk, Bob Kiaii.   

Abstract

BACKGROUND: Simultaneous integrated coronary artery revascularization combines coronary artery bypass surgery and percutaneous coronary intervention into a single procedure. This approach provides immediate, complete and optimal myocardial revascularization in a less invasive manner. Because simultaneous integrated coronary revascularization necessitates two distinct anticoagulation protocols for the surgical and percutaneous aspects of the procedure, combining these anticoagulation protocols carries a bleeding risk. Using a single anticoagulant to facilitate the necessities of both aspects of the integrated approach may alleviate this risk. CASE
PRESENTATION: A 45-year-old man with an occluded left anterior descending artery and a moderately stenotic circumflex artery underwent simultaneous integrated coronary revascularization. Bivalirudin was used to achieve anticoagulation for the duration of the procedure. The patient was asymptomatic with excellent patency of both the bypass graft and the stented circumflex artery via angiography at 10 months.
CONCLUSION: Bivalirudin can be used to effectively achieve a unified anticoagulation protocol for simultaneous integrated revascularization.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19584974      PMCID: PMC2723028          DOI: 10.1016/s0828-282x(09)70514-8

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  5 in total

Review 1.  Safety of glycoprotein IIb/IIIa inhibitors in urgent or emergency coronary artery bypass graft surgery.

Authors:  Doret K F Cheng; Cynthia A Jackevicius; Peter Seidelin; Chris Feindel; Jean Lucien Rouleau
Journal:  Can J Cardiol       Date:  2004-02       Impact factor: 5.223

2.  Prolonging patency--choosing coronary bypass grafts.

Authors:  Bruce W Lytle
Journal:  N Engl J Med       Date:  2004-11-25       Impact factor: 91.245

3.  Integrated left anterior small thoracotomy and angioplasty for coronary artery revascularization.

Authors:  C T Lloyd; A M Calafiore; P Wilde; R Ascione; L Paloscia; C R Monk; G D Angelini
Journal:  Ann Thorac Surg       Date:  1999-09       Impact factor: 4.330

4.  Does clopidogrel increase blood loss following coronary artery bypass surgery?

Authors:  Michael W A Chu; Steve R Wilson; Richard J Novick; Larry W Stitt; MacKenzie A Quantz
Journal:  Ann Thorac Surg       Date:  2004-11       Impact factor: 4.330

Review 5.  Bivalirudin: pharmacology and clinical applications.

Authors:  Nicolas W Shammas
Journal:  Cardiovasc Drug Rev       Date:  2005
  5 in total
  1 in total

1.  Production and characterization of hirudin variant-1 by SUMO fusion technology in E. coli.

Authors:  Wuguang Lu; Xueting Cai; Zhenghua Gu; Yuzheng Huang; Binbin Xia; Peng Cao
Journal:  Mol Biotechnol       Date:  2013-01       Impact factor: 2.695

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.